Paper Details

  1. Home
  2. Paper Details

Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT): the role of anti-IgE in severe paediatric eczema: study protocol for a randomised controlled trial.

Author: ChanSusan, ChenTao, CorneliusVictoria, JahanRahi, LackGideon, RadulovicSuzana, WanMandy

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study aimed to assess whether anti-IgE treatment (omalizumab) improves eczema compared to placebo in children with severe childhood eczema.
Paper Details　
Original Abstract of the Article :
The evidence for systemic treatments for severe childhood eczema is limited and largely based on extrapolation of data from adult studies. Current therapies are often immunosuppressant and may be associated with both short- and long-term side effects. There is increasing in vitro and murine-model ev...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361704/

データ提供：米国国立医学図書館（NLM）

A New Hope for Severe Childhood Eczema: The ADAPT Trial

The field of pediatric dermatology is always seeking new and effective treatments for severe childhood eczema, a condition that can significantly impact a child's quality of life. This study protocol outlines a randomized controlled trial, ADAPT (Atopic Dermatitis Anti-IgE Paediatric Trial), to investigate the potential of anti-IgE treatment (omalizumab) in managing severe childhood eczema. The researchers aim to assess the efficacy of omalizumab compared to a placebo, potentially offering a new treatment option for children with severe eczema.

Anti-IgE Treatment: A Potential Breakthrough for Eczema

The ADAPT trial aims to assess the potential of omalizumab, an anti-IgE treatment, for managing severe childhood eczema. This research could lead to a significant breakthrough in the treatment of this challenging condition, offering hope for children who have not responded to conventional therapies. This potential breakthrough is like finding a hidden spring of healing in the heart of the desert.

Addressing the Needs of Children with Severe Eczema

The study highlights the importance of finding effective treatments for severe childhood eczema. This condition can significantly impact a child's physical and emotional well-being, affecting their sleep, social interactions, and overall quality of life. This research aims to address the urgent need for safe and effective treatments for children with severe eczema.

Dr.Camel's Conclusion

Severe childhood eczema, like a stubborn desert sandstorm, can be a difficult condition to manage. The ADAPT trial offers a glimmer of hope for children who suffer from this debilitating condition. This research, like a camel caravan carrying precious supplies across a desolate landscape, brings the promise of new treatments and improved quality of life for children with severe eczema.

Date :
  1. Date Completed 2018-02-26
  2. Date Revised 2021-01-09
Further Info :

Pubmed ID

28330497

DOI: Digital Object Identifier

PMC5361704

Related Literature

Article Analysis
・Effective treatment of eczema
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.